The sleep-and-brain-imaging group posted record FY26 revenue of about A$60.3 million, but helium-hit MEG shipments, a delayed US Somfit launch and a surprise director exit left investors underwhelmed ahead of the audited result due late August.
Cochlear (ASX:COH) has gained 7.54% as the hearing-implant leader enters a crucial earnings reset after a difficult FY26. Earlier in the year, the company reducedUnderlying Profitguidance to AUD 290mn-AUD 330mn, citing softer implant demand, regional delivery risks,Marginpressure and higher restructuring costs. The recent share-price …
PolyNovo (ASX:PNV) has gained 7.43% as the wound-care company closes FY26 with record revenue and a clear improvement in cash generation. Unaudited group revenue reached AUD 150.0mn, commercial sales increased across the US and international markets, and free cash flow turned positive. The result …
Medical Developments International (ASX:MVP) has gained 8.7% as Penthrox growth begins translating more clearly into cash generation. The June-quarter update showed positive free cash flow for both Q4 and FY26, alongside higher pain-management revenue and expanding Penthrox volumes in Australia and Europe. The improvement …
Pro Medicus (ASX:PME) has jumped 13.04% as the medical-imaging software group continues to build its contractedRevenuepipeline while expanding the role of AI within the Visage ecosystem. June brought multiple contract wins and renewals alongside a heads of agreement with Echo IQ, reinforcing the company’s …
Cochlear Limited (ASX:COH) shares were trading atA$141.33 on 18 August 2026 at 12:48 pm, representing a gain of7.68%, or A$10.08, as investors responded to the company's FY26 financial update. Cochlear reported sales revenue of A$2.3 billion for the year ended June 2026, an increase …
Pro Medicus Limited (ASX:PME) shares were trading atA$197.14 on 18 August 2026 at 12:57 pm, up12.10%, or A$21.28, after the medical imaging software company released its FY26 results. Revenue from ordinary activities increased22.9% to A$261.7 million, while underlying net profit after tax rose 24.1% …
CSL Limited (ASX:CSL) was trading at AUD 157.57, up 17.07% at the time of writing on 18 August 2026. The movement comes as investors assess the company’s FY26 full-year results, transformation initiatives and outlook across its plasma, vaccines and specialty healthcare businesses.
Fisher & Paykel Healthcare Corporation Limited (ASX:FPH) was trading at AUD 34.79, down 1.08% at the time of writing on 18 August 2026. The company’s share price movement comes as investors continue to assess its respiratory care business, medical deviceDemandand global healthcare market conditions.
ResMed Inc (ASX:RMD) was trading at AUD 31.18, down 1.42% at the time of writing on 18 August 2026. The company’s share price movement comes as investors continue to assess its latest financial performance, sleep health technology portfolio and broader healthcare market position.